Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Income from Continuing Operations: 2021-2024

Historic Income from Continuing Operations for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Income from Continuing Operations fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Income from Continuing Operations is $8.0 million, which was up 114.71% from -$54.4 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Income from Continuing Operations high stood at $8.0 million for FY2024, and its period low was -$54.4 million during FY2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$35.5 million (2022), whereas its average is -$27.3 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 82.56% in 2022, then spiked by 114.71% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$19.5 million in 2021, then slumped by 82.56% to -$35.5 million in 2022, then crashed by 53.07% to -$54.4 million in 2023, then soared by 114.71% to $8.0 million in 2024.